Genomic Valley Biotech Ltd - 539206 - Disclosure Of Related Party Transactions Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31.03.2021
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the disclosure of Related Party Transactions for the half year ended 31.03.2021. Genomic Valley Biotech Ltd - 539206 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Yogesh AgrawalDesignation :- Managing Director / Whole Time Director Genomic Valley Biotech Ltd - 539206 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith the certificate pursuant to Regulation 74 (5) of SEBI (Depositories & Participants) Regulations, 2018 for the quarter ended on 30th June, 2021. Genomic Valley Biotech Ltd - 539206 - Shareholding for the Period Ended June 30, 2021
Genomic Valley Biotech Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here Genomic Valley Biotech Ltd - 539206 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the Regulation 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of Newspaper advertisements of the Extract of Audited Financial Results for the quarter and year ended 31.03.2021 approved in Board Meeting of the Company held on 29.06.2021. Genomic Valley Biotech Ltd - 539206 - Closure of Trading Window
Pursuant to the Code of Conduct for Prevention of Insider Trading of the Company under SEBI(Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform you that the trading window for the purpose of trading in the securities of the Company by its Designated persons shall remain closed from July 01, 2021 till 48 (Forty Eight) hours after the conclusion of the Meeting of the Board of Directors of the Company to be held to consider and approve the Un-Audited Financial Results of the Company for the quarter and three months ended June 30, 2021. Genomic Valley Biotech Ltd - 539206 - Results-Financial Results For The Quarter And Year Ended 31.03.2021
Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ('Company') in its meeting held today approved the Audited Financial Results (Standalone) for the Quarter and Year ended 31st March, 2021 of the Company as per Indian Accounting Standards (IND-AS) along with the Independent Auditor's Report. Copy of the results along with the Independent Auditor's Report of Statutory Auditors is attached herewith for your perusal. Genomic Valley Biotech Ltd - 539206 - Outcomes Of Board Meeting
Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ('Company') in its meeting held today approved the Audited Financial Results (Standalone) for the Quarter and Year ended 31st March, 2021 of the Company as per Indian Accounting Standards (IND-AS) along with the Independent Auditor's Report. Copy of the results along with the Independent Auditor's Report of Statutory Auditors is attached herewith for your perusal. Genomic Valley Biotech Ltd - 539206 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to the Regulation 24A of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, we hereby submit Annual Compliance Report for the Financial Year 2020-21 issued by Mr. Rohit Batham representative of Rohit Batham & Associates, Company Secretaries.